Predicting erenumab adverse events with single-cell genomics.

Vgontzas, Angeliki; Renthal, William

Vgontzas, Angeliki; Renthal, William.

Affiliation

Vgontzas A; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Renthal W; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: wrenthal@bwh.harvard.edu.

Lancet ; 396(10244): 95-96, 2020 07 11.

Article in En | MEDLINE | ID: mdl-32653068

Subject(s)

Antibodies, Monoclonal, Humanized/adverse effects; Calcitonin Gene-Related Peptide Receptor Antagonists/adverse effects; Genomics/methods; Receptors, Calcitonin Gene-Related Peptide/genetics; Animals; Antibodies, Monoclonal, Humanized/therapeutic use; Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use; Clinical Decision Rules; Clinical Trials as Topic; Constipation/chemically induced; Hospitalization/statistics & numerical data; Humans; Mice; Migraine Disorders/drug therapy; Peripheral Nervous System/cytology; Peripheral Nervous System/metabolism; Placebos/administration & dosage

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Calcitonin Gene-Related Peptide / Genomics / Antibodies, Monoclonal, Humanized / Calcitonin Gene-Related Peptide Receptor Antagonists Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Lancet Year: 2020 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google